ZLSCF (ZYUS Life Sciences) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLSCF ZYUS Life Sciences Corp ZLSCF
21 GF Score
Price $0.60
GF Value $0.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ZYUS Life Sciences  (OTCPK:ZLSCF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ZYUS Life Sciences Cyclically Adjusted PB Ratio Related Terms


ZYUS Life Sciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Cyclically Adjusted PB Ratio Chart

ZYUS Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.43 0.56 0.52

ZYUS Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.44 0.44 0.29 0.04

ZLSCF vs SKYI, CBDY, NPHC: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's Cyclically Adjusted PB Ratio falls into.


ZLSCF
21GF Score
ZYUS Life Sciences Corp ZLSCF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZYUS Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ZYUS Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, ZYUS Life Sciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.236/133.5265*133.5265
=-0.236

Current CPI (Jun. 2026) = 133.5265.

ZYUS Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.424 101.765 1.868
201612 1.384 101.449 1.822
201703 1.415 102.634 1.841
201706 1.486 103.029 1.926
201709 1.541 103.345 1.991
201712 1.502 103.345 1.941
201803 1.408 105.004 1.790
201806 1.387 105.557 1.755
201809 1.399 105.636 1.768
201812 1.258 105.399 1.594
201903 1.330 106.979 1.660
201906 1.350 107.690 1.674
201909 1.338 107.611 1.660
201912 1.367 107.769 1.694
202003 1.120 107.927 1.386
202006 1.183 108.401 1.457
202009 1.204 108.164 1.486
202012 1.278 108.559 1.572
202103 1.332 110.298 1.613
202106 1.371 111.720 1.639
202109 1.336 112.905 1.580
202112 1.344 113.774 1.577
202203 1.376 117.646 1.562
202206 1.282 120.806 1.417
202209 1.185 120.648 1.311
202212 0.091 120.964 0.100
202303 1.198 122.702 1.304
202306 0.552 124.203 0.593
202309 0.495 125.230 0.528
202312 0.247 125.072 0.264
202403 0.209 126.258 0.221
202406 0.160 127.522 0.168
202409 0.148 127.285 0.155
202412 -0.050 127.364 -0.052
202503 -0.070 129.181 -0.072
202506 -0.092 129.892 -0.095
202509 -0.119 130.287 -0.122
202512 -0.192 130.366 -0.197
202603 -0.213 132.262 -0.215
202606 -0.236 133.527 -0.236

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?

Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be overvalued. The current stock price of $0.60 is trading 9.1% above its estimated GF Value™ of $0.55. GuruFocus considers ZYUS Life Sciences to be Fairly Valued.

Key valuation signals for ZLSCF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $0.55 vs. price of $0.60 (9.1% above fair value)
  • GF Score™: 21/100 with 6 warning signs

No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score

Get the complete analysis for ZLSCF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.55
GF Value